As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

The FDA will now allow biotechs to ask agency staff for “quick clarifications” via email. Elsewhere, Novartis hiked guidance for two top drugs and a startup nearing “unicorn” status secured a ...

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for ...

The cell therapy maker said Thursday the raise will support an ongoing trial of its experimental treatment for the ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...

At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set the stage for additional growth ...

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

After a year of heightened expectations over the promise of drugs that co-target PD-1 and VEGF, some important mid- and late-stage datasets are emerging at the annual World Conference on Lung Cancer ...

Roche is investing $75 million in Freenome as part of the deal, which comes a year after the Swiss company led a $254 million ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

The company declined to comment on Gottlieb’s appointment, which comes as it works to improve its relationship with federal ...